Equity · Healthcare
UnitedHealth Group Incorporated (UNH) perpetual futures
UNH perpetual futures on 14 crypto exchanges – live perp price vs the stock, funding rate, open interest and where to trade UNHUSDT.
UnitedHealth Group operates as a comprehensive healthcare enterprise with divisions for health benefits, care delivery, technology consulting, and pharmacy services.
Price chart
Use the left and right arrow keys to inspect points on the chart.
Trading data
Perpetual market activity
14/14 live markets
Trading data
Perpetual market activity
Spot performance
Venue matrix
14 markets
Some venue links are sponsored. We may receive a commission, and eligible users may occasionally receive trading-fee discounts, at no additional cost to you.
| Trade | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
XT.com | Trade | UNH/USDT | Trading | $335.87 | 0.0% APR 0.000% every 8h | +8.3 bps | $198.2K | $132.4K | - | USDT | 20x | |
HTX | Trade | UNH/USDT | Trading | $334.78 | 0.0% APR 0.000% every 8h | +46.0 bps | $1.2M | $126K | $13.6K | USDT | - | |
MEXC | Trade | UNH/USDT | Trading | $336.13 | 0.0% APR 0.000% every 8h | +23.5 bps | $160.2K | $102.2K | $5M | USDT | 100x | |
Bitunix | Trade | UNH/USDT | Trading | $335.90 | -4.0% APR -0.00362% every 8h | +10.1 bps | $68.6K | $73.5K | $51.4K | USDT | 20x | |
Binance | Trade | UNH/USDT | Trading | $335.86 | 0.0% APR 0.000% every 8h | +8.3 bps | $53.2K | $42.2K | $200.5K | USDT | - | |
BloFin | Trade | UNH/USDT | Trading | $335.98 | +1.7% APR +0.00152% every 8h | +0.9 bps | - | $20.1K | $18.7K | USDT | 20x | |
LBank | Trade | UNH/USDT | Trading | $336.18 | 0.0% APR 0.000% every 8h | +22.3 bps | $148.2K | $14.2K | $34.4K | USDT | 50x | |
Bitget | Trade | UNH/USDT | Trading | $336.21 | 0.0% APR 0.000% every 8h | +0.6 bps | $395.5K | $13.2K | $188.2K | USDT | 20x | |
OKX | Trade | UNH/USDT | Trading | $335.62 | 0.0% APR 0.000% every 8h | +23.8 bps | $5.1K | $11.5K | $63.2K | USDT | 20x | |
Gate.io | Trade | UNH/USDT | Trading | $335.77 | 0.0% APR 0.000% every 8h | +34.0 bps | $5.1K | $4.8K | $53.2K | USDT | 25x | |
Bybit | Trade | UNH/USDT | Trading | $335.78 | 0.0% APR 0.000% every 8h | +26.2 bps | $50.6K | $973 | $100.3K | USDT | 25x | |
Crypto.com Exchange | Trade | UNH/USD | Trading | $335.31 | +5.0% APR +0.00057% every 1h | +16.4 bps | $1.9K | $0 | $187.8 | USD | 50x | |
Deepcoin | Trade | UNH/USDT | Trading | $336.01 | - | +13.7 bps | - | $685.3K | - | USDT | 25x | |
BingX | Trade | UNH-USDT | Trading | $335.91 | +5.5% APR +0.00500% every 8h | +8.3 bps | $141.7K | $667.1K⚠ | $3.2K | USDT | - |
Unverified volume: implausibly high against open interest, a typical sign of wash trading. These venues are listed last.
Tokenized wrappers of the real stock, tradable on-chain and on crypto exchanges around the clock. Premium/discount compares the token price to our stock reference price. Data: CoinMarketCap · Robinhood · DexScreener · GeckoTerminal.
| Product | Price | Premium vs stock | 24h Vol. | Market Cap | Chains |
|---|---|---|---|---|---|
| UNHonOndo GM | $337.81 | +0.91% | $411k | $1.1M | Ethereum · BNB Smart Chain (BEP20) · Solana |
| UNHXxStocks | $333.39 | -0.41% | $40k | $519k | Solana · Arbitrum · BNB Smart Chain (BEP20) · Ink |
| UNHRobinhood | – | – | – | $18k | Robinhood Chain |
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100k
Tradability
Execution quality
Entry cost and depth per venue at $1k–$100kBroad liquidity · 9 of 14 venues absorb $10k · Typical cost: +16.4 bps – +20.8 bps
Too thin: OKX, Gate.io, Crypto.com Exchange, Deepcoin
No fresh book data: BloFin
Taker execution estimate incl. approx. fees - maker fills are not guaranteed.
Best venues for this underlying
Best liquidity
UNHTightest spread
UNHHighest volume
UNHFunding history
Stored venue snapshots by market
Funding history
Stored venue snapshots by marketNext catalyst
Catalysts
Next catalyst
Catalysts
No unusual perp activity right now.
Research data
Analysts, filings and peer context
Research data
Analysts, filings and peer context
Estimates
6Company events
6Peer comparison
Similar listed perpsRevenue mix
Latest annualAnalysts
Price targets in USD| Consensus rating | Buy |
|---|---|
| Average 12-month price target | $477.50 |
| 12-month target range (low – high) | $380 – $531 |
| Ratings in the provider's consensus | 52 |
Price targets as of 2026-11-21
Analyst rating history
Ratings| Month | Strong buy | Buy | Hold | Sell | Strong sell |
|---|---|---|---|---|---|
| Nov 2026 | 7 | 16 | 5 | 0 | 0 |
| Oct 2026 | 7 | 15 | 5 | 0 | 0 |
| Sep 2026 | 7 | 16 | 4 | 0 | 0 |
| Aug 2026 | 7 | 16 | 5 | 0 | 0 |
| Jul 2026 | 6 | 17 | 5 | 1 | 0 |
| Jun 2026 | 6 | 17 | 5 | 1 | 0 |
| May 2026 | 7 | 16 | 5 | 1 | 0 |
| Apr 2026 | 7 | 16 | 5 | 2 | 0 |
| Mar 2026 | 6 | 16 | 6 | 2 | 0 |
| Feb 2026 | 6 | 15 | 6 | 2 | 0 |
| Jan 2026 | 6 | 15 | 6 | 2 | 0 |
| Dec 2025 | 6 | 14 | 6 | 2 | 0 |
Ownership
Institutional · 2026-Q3Reference market activity
UNH-PERPPrice performance
11Insider activity
FY2026 Q4Insider transactions
25UnitedHealth CEO Noel Timothy John reported 587 common shares withheld for taxes (F-Tax) at $402.94 on 2026-11-11, leaving 17,148 shares owned.
A Form 3 initial statement was filed for director Madeline S. Bell of UnitedHealth Group, listing one Common Stock holding row with 0 shares at $0.00 and 0 shares owned after.
Director John H Noseworthy received a 240-share Common Stock award (code A, grant/compensation) on 2026-10-01, leaving 7,902 shares owned. Form 4 filed 2026-10-05.
Director Valerie MD Montgomery received an award of 257 shares of UnitedHealth common stock on 2026-10-01, under code A (grant/compensation, not an open-market purchase). Ownership after the transaction was 8,180 shares.
UnitedHealth Group director Frederick William McNabb III received a grant (A-Award) of 291 Common Stock shares on 2026-10-01, held directly, raising his ownership to 15,810 shares. The award was compensation, not a purchase; no open-market buy or sale occurred.
UnitedHealth Group director Scott Gottlieb received an award of 257 common shares at $0.00 on 2026-10-01, per a Form 4 filed 2026-10-05, leaving him with 921 shares owned.
Director Kristen Gil received a 240-share Common Stock award on 2026-10-01, a grant/compensation that was not an open-market purchase. She owned 2,867 shares afterward.
Director Paul R. Garcia received awards totaling 258 shares of UnitedHealth Group common stock on 2026-10-01, via 2 A-Award grants at $0.00 per share. Holdings after were 4,180 and 4,077 shares.
UnitedHealth Group director Timothy Patrick Flynn received a grant of 262 Common Stock shares on 2026-10-01, bringing his holdings to 11,205 shares.
Director Charles D. Baker received an award of 257 Common Stock shares of UnitedHealth Group, a grant/compensation (code A, not a purchase), at $0.00 on 2026-10-01, leaving 2,668 shares owned.
Director Frederick William McNabb III received a 57-share Common Stock award on 2026-09-22, an A-Award grant at $0.00, leaving him with 15,519 shares owned.
UnitedHealth Group officer Dennis Andrew Stankiewicz was awarded 51 shares of common stock on Sep 22, 2026, bringing his holdings to 10,109 shares. The Form 4 was filed Sep 24, 2026.
Director Charles D. Baker received an award of 15 shares of UnitedHealth Group common stock on 2026-09-22 at $0.00 under an A-Award grant, leaving him with 2,411 shares owned.
Director Timothy Patrick Flynn received an award of 68 shares of UnitedHealth Group common stock on 2026-09-22, at $0.00 per share, bringing his holdings to 10,943 shares. The Form 4 was filed 2026-09-24.
Director John H Noseworthy received an award of 46 common shares of UnitedHealth Group on 2026-09-22, a compensation grant rather than an open-market purchase, bringing his holdings to 7,662 shares.
UnitedHealth Group director Scott Gottlieb received a 5-share Common Stock award on 2026-09-22, an A-Award grant rather than an open-market purchase; he held 664 shares after.
UnitedHealth EVP & Chief Legal Officer Zaetta Christopher R received 67 common shares via an award (A) on 2026-09-22, bringing his holdings to 15,927 shares.
Director/CEO Hemsley received 50 common shares via an A-Award (compensation grant, not a purchase) on 2026-09-22, leaving 177,690 shares owned. Filed on Form 4.
Director Valerie Montgomery Rice received a grant of 47 shares of UnitedHealth Group common stock at $0.00 per share, bringing her holdings to 7,923 shares.
UnitedHealth Group director Paul R. Garcia received an award of 16 shares of common stock on 2026-09-22, bringing his holdings to 3,922 shares, per a Form 4 filed 2026-09-24.
Director Kristen Gil received a grant of 10 Common Stock shares in UnitedHealth Group at $0.00 on 2026-09-22, bringing direct holdings to 2,627 shares. This was a compensation award, not an open-market purchase.
UnitedHealth Group officer Patrick Hugh Conway received 91 shares of Common Stock on 2026-09-22 via an A-Award grant, leaving him with 15,419 shares owned.
UnitedHealth CFO Wayne S DeVeydt received a grant of 106 Common Stock shares on 2026-09-22, an award that was not an open-market purchase. He held 18,676 shares afterward.
UnitedHealth Group officer Timothy John Noel received a grant of 84 shares of Common Stock on Sept 22, 2026, at $0.00 per share, an award rather than a purchase, bringing his holdings to 17,735 shares.
Filings
69 · Latest SEC filingsUnitedHealth CEO Noel Timothy John reported 587 common shares withheld for taxes (F-Tax) at $402.94 on 2026-11-11, leaving 17,148 shares owned.
A Form 3 initial statement was filed for director Madeline S. Bell of UnitedHealth Group, listing one Common Stock holding row with 0 shares at $0.00 and 0 shares owned after.
UnitedHealth Group director Frederick William McNabb III received a grant (A-Award) of 291 Common Stock shares on 2026-10-01, held directly, raising his ownership to 15,810 shares. The award was compensation, not a purchase; no open-market buy or sale occurred.
Director John H Noseworthy received a 240-share Common Stock award (code A, grant/compensation) on 2026-10-01, leaving 7,902 shares owned. Form 4 filed 2026-10-05.
Director Valerie MD Montgomery received an award of 257 shares of UnitedHealth common stock on 2026-10-01, under code A (grant/compensation, not an open-market purchase). Ownership after the transaction was 8,180 shares.
UnitedHealth Group director Scott Gottlieb received an award of 257 common shares at $0.00 on 2026-10-01, per a Form 4 filed 2026-10-05, leaving him with 921 shares owned.
Director Kristen Gil received a 240-share Common Stock award on 2026-10-01, a grant/compensation that was not an open-market purchase. She owned 2,867 shares afterward.
Director Paul R. Garcia received awards totaling 258 shares of UnitedHealth Group common stock on 2026-10-01, via 2 A-Award grants at $0.00 per share. Holdings after were 4,180 and 4,077 shares.
UnitedHealth Group director Timothy Patrick Flynn received a grant of 262 Common Stock shares on 2026-10-01, bringing his holdings to 11,205 shares.
Director Charles D. Baker received an award of 257 Common Stock shares of UnitedHealth Group, a grant/compensation (code A, not a purchase), at $0.00 on 2026-10-01, leaving 2,668 shares owned.
Director Frederick William McNabb III received a 57-share Common Stock award on 2026-09-22, an A-Award grant at $0.00, leaving him with 15,519 shares owned.
Director Timothy Patrick Flynn received an award of 68 shares of UnitedHealth Group common stock on 2026-09-22, at $0.00 per share, bringing his holdings to 10,943 shares. The Form 4 was filed 2026-09-24.
UnitedHealth EVP & Chief Legal Officer Zaetta Christopher R received 67 common shares via an award (A) on 2026-09-22, bringing his holdings to 15,927 shares.
Director Valerie Montgomery Rice received a grant of 47 shares of UnitedHealth Group common stock at $0.00 per share, bringing her holdings to 7,923 shares.
UnitedHealth Group officer Patrick Hugh Conway received 91 shares of Common Stock on 2026-09-22 via an A-Award grant, leaving him with 15,419 shares owned.
UnitedHealth Group officer Timothy John Noel received a grant of 84 shares of Common Stock on Sept 22, 2026, at $0.00 per share, an award rather than a purchase, bringing his holdings to 17,735 shares.
UnitedHealth Group officer Dennis Andrew Stankiewicz was awarded 51 shares of common stock on Sep 22, 2026, bringing his holdings to 10,109 shares. The Form 4 was filed Sep 24, 2026.
Director Charles D. Baker received an award of 15 shares of UnitedHealth Group common stock on 2026-09-22 at $0.00 under an A-Award grant, leaving him with 2,411 shares owned.
Director John H Noseworthy received an award of 46 common shares of UnitedHealth Group on 2026-09-22, a compensation grant rather than an open-market purchase, bringing his holdings to 7,662 shares.
Director/CEO Hemsley received 50 common shares via an A-Award (compensation grant, not a purchase) on 2026-09-22, leaving 177,690 shares owned. Filed on Form 4.
UnitedHealth Group director Paul R. Garcia received an award of 16 shares of common stock on 2026-09-22, bringing his holdings to 3,922 shares, per a Form 4 filed 2026-09-24.
UnitedHealth Group officer Erin McSweeney reported a grant of 53 Common Stock shares at $0.00 on 2026-09-22, leaving 15,654 shares owned.
UnitedHealth Group director Scott Gottlieb received a 5-share Common Stock award on 2026-09-22, an A-Award grant rather than an open-market purchase; he held 664 shares after.
Director Kristen Gil received a grant of 10 Common Stock shares in UnitedHealth Group at $0.00 on 2026-09-22, bringing direct holdings to 2,627 shares. This was a compensation award, not an open-market purchase.
UnitedHealth CFO Wayne S DeVeydt received a grant of 106 Common Stock shares on 2026-09-22, an award that was not an open-market purchase. He held 18,676 shares afterward.
The reporting person disposed of 1,209 shares of common stock to cover tax withholding obligations, at a price of $399.66 per share.
On August 21, 2026, an officer sold 1,169 common shares at $390 each, reducing holdings to 15,328 shares.
On August 11, 2026, Chief Accounting Officer Dennis Andrew Stankiewicz of UnitedHealth Group disposed of 233 common shares at $402.19 each via tax withholding (code F), leaving 10,058 shares owned.
Patrick Hugh Conway, CEO of Optum at UnitedHealth Group, sold 500 shares of Common Stock at $410 each on August 5, 2026.
UnitedHealth Group director John H. Noseworthy received an award of 206 common shares on 2026-07-01, bringing his total ownership to 7,616 shares.
Director Valerie Montgomery Rice received a grant of 220 UnitedHealth Group common shares on 2026-07-01, bringing her total holdings to 7,876 shares. This was a compensation award, not an open-market purchase.
UnitedHealth Group director Frederick William McNabb III received a grant of 250 shares of common stock on 2026-07-01, bringing his total ownership to 15,462 shares.
UnitedHealth Group director Scott Gottlieb was granted 210 shares of common stock on 2026-07-01 as compensation, bringing his total holdings to 659 shares.
Director Gil Kristen was awarded 206 shares of UnitedHealth common stock on 2026-07-01 as compensation, bringing his total holdings to 2,617 shares.
Director Paul R. Garcia received two stock awards totaling 220 common shares of UnitedHealth Group at $0.00 on July 1, 2026. These are compensation grants, not open-market purchases; he held 3,906 shares after.
Director Timothy Flynn was awarded 225 shares of UnitedHealth common stock as compensation, bringing his total holdings to 10,875 shares.
Charles D. Baker, a director at UnitedHealth Group, received a grant of 220 common shares on 2026-07-01, bringing his total ownership to 2,396 shares.
Director Timothy Patrick Flynn received an award of 61 UnitedHealth Group common shares on 2026-06-23, bringing his total holdings to 10,650 shares.
Christopher R. Zaetta (EVP & Chief Legal Officer) received a grant of 61 shares of UnitedHealth common stock on 2026-06-23, bringing his total holdings to 15,860 shares.
Patrick Hugh Conway, CEO of Optum at UnitedHealth Group, was awarded 82 shares of common stock (compensation grant) on 2026-06-23, bringing his total ownership to 16,997 shares.
Timothy John Noel, CEO of UHC, was awarded 76 shares of UnitedHealth Group common stock on 2026-06-23 as compensation, bringing his ownership to 17,651 shares.
UNH CFO Wayne S. DeVeydt was awarded 112 shares of common stock as compensation on 2026-06-23, bringing his total holdings to 19,779 shares.
Stephen Hemsley (CEO) received a grant of 46 UnitedHealth Group common shares on 2026-06-23, raising his ownership to 48,099 shares. This was a compensation award, not an open-market purchase.
UnitedHealth Group EVP & Chief People Officer Erin McSweeney received a grant of 48 common shares on 2026-06-23, bringing her total holdings to 15,601 shares.
Director John H. Noseworthy was awarded 41 shares of UnitedHealth common stock on 2026-06-23, bringing his total holdings to 7,410 shares.
Director Paul R. Garcia received an award of 13 shares of UnitedHealth Group common stock on 2026-06-23, bringing his total holding to 3,686 shares. This was a grant, not an open-market purchase.
Director Valerie Montgomery Rice received an award of 41 shares of UnitedHealth common stock on 2026-06-23, bringing her total holdings to 7,656 shares.
Director Gil Kristen was awarded 8 shares of UnitedHealth Group common stock on 2026-06-23, bringing his total holdings to 2,411 shares. This was a grant, not an open-market purchase.
Director Scott Gottlieb was awarded 3 shares of UnitedHealth Group common stock on 2026-06-23, bringing his ownership to 449 shares.
UNH Chief Accounting Officer Dennis Stankiewicz received a grant (A-Award) of 51 common shares on 2026-06-23, bringing his total ownership to 10,257 shares.
Director Charles D. Baker was granted 13 shares of UnitedHealth Group common stock (Award, $0.00), bringing his total holdings to 2,176 shares.
Director Frederick W. McNabb III was awarded 50 shares of UnitedHealth common stock on 2026-06-23, bringing his total holdings to 15,212 shares. This was a compensation grant, not an open-market purchase.
Patrick Hugh Conway, CEO of Optum at UnitedHealth Group, had 687 shares of common stock withheld for taxes on 2026-06-05 at $399.47 per share, leaving 16,914 shares owned afterward.
Patrick Conway (CEO, Optum) had 204 UnitedHealth common shares withheld to cover taxes at $377.92 per share, leaving 17,601 shares owned.
UnitedHealth Group EVP & Chief Legal Officer Christopher R. Zaetta had 134 shares of common stock withheld to cover taxes at $377/share, leaving 16,582 shares owned afterward.
Transcripts
Earnings callsFY2026 Q32026-10-13
Earnings calls
AI summary
positiveUnitedHealth Group reported Q3 2026 revenue of $113 billion and adjusted EPS of $4.69, up from $2.92 a year ago, with a consolidated medical care ratio of 88.4% versus 89.9% last year. Management raised 2026 adjusted EPS guidance to at least $20.50 and said the lower end of its 13%-16% long-term growth range is a reasonable starting point for 2027, adding that current analyst consensus for 2027 may understate the opportunity. Medicare Advantage margins are now expected near the top end of the 2%-4% range, and core Medicaid margins are expected moderately better than negative 1%, which management views as a trough year. Commercial trends remain above the initial 11% expectation, driven by No Surprises Act dispute cost acceleration, clinician cost intensity, and high-cost specialty drugs. The company cited AI-enabled chart summarization, prior authorization reforms, and integrated pharmacy and medical care as modernization efforts underway across the enterprise.
Key takeaways
- Q3 2026 revenue was $113 billion and adjusted EPS was $4.69, up from $2.92 a year ago, with consolidated medical care ratio of 88.4% versus 89.9% last year.
- 2026 adjusted EPS guidance is now at least $20.50, which management views as a solid run rate on which to grow.
- Medicare Advantage 2026 margins are now expected near the top end of the 2%-4% range, attributed to medical trend and cost management initiatives and durable 2026 product offerings.
- Core Medicaid margins for 2026 are expected moderately better than negative 1%, with 2026 viewed as a trough year and rate-appropriate margins targeted by 2028.
- Prior authorization reforms are on track to be fully implemented by year-end, reducing total prior authorizations by 30% and prior authorizations for people under age 18 by two-thirds.
Financial highlights
- Q3 2026 revenue was $113 billion and adjusted earnings per share was $4.69, up from $2.92 a year ago.
- Consolidated medical care ratio was 88.4% for the quarter, compared to 89.9% last year.
- The company repurchased $5 billion of UNH stock through the third quarter and paid $6.2 billion in dividends year to date, expecting to exceed $8 billion by year-end.
- Debt-to-capital ratio was 41.7% at quarter close, and the company remains on track to approach 40% by year-end.
Guidance
- Full-year 2026 adjusted EPS guidance is at least $20.50, reflecting third quarter performance balanced by expected investments in the final months of the year.
- For 2027, management said current analyst consensus may understate the opportunity and that the lower end of the 13%-16% long-term growth range is a more reasonable starting point.
- Medicare Advantage 2026 margins are now expected near the top end of the 2%-4% range, and core Medicaid margins are expected moderately better than negative 1%.
- The company plans to provide a more comprehensive 2027 outlook before year-end, and Optum Health aims to reach its 6%-8% target margin range by 2028.
Q&A themes
- Medicaid performance and margin recovery: analysts asked about the third quarter run rate, elevated behavioral, specialty pharmacy, home and community-based, and inpatient trends, and the path toward targeted margins by 2028.
- Medicare Advantage and commercial selling seasons: management cited D-SNP, C-SNP, and high-value HMO focus, footprint expansion to more than 94% of Medicare eligibles, strong national account persistency, and Optum Rx retention in the high 90s.
- Optum Health and Optum Insight growth: management pointed to 20 million patients served with about 4 million in fully accountable relationships, new post-acute risk products, and AI-first products such as Optum Integrity One with 15 clients implemented and 24 more implementing.
- Commercial trend and No Surprises Act disputes: commercial benefit trends exceed the initial 11% expectation, with arbitration awards approaching nearly 6% of total medical spend in some regions, which management called excessive.
Risks
- Commercial medical cost trends are exceeding the initial 11% expectation due to No Surprises Act-related costs, greater clinician cost intensity, and high-cost specialty drugs, which management said will stretch the timeline to reach long-term commercial margins.
- Management remains respectful of elevated care intensity and ongoing clinician pricing pressure and is not assuming any deceleration to historical patterns.
- Medicaid results depend on the timing and adequacy of state funding across several markets, and rate updates remain uneven despite collaboration with state partners.
FY2026 Q22026-07-16
Earnings calls
AI summary
positiveUnitedHealth Group reported second quarter 2026 adjusted earnings per share of $6.38 versus $4.08 a year ago, with total revenues of $112 billion and operating earnings of $8 billion, up 55% year-over-year. Management raised full-year 2026 adjusted EPS guidance to $19.50 to $20, citing better-than-expected Medicare Advantage results while commercial cost trends remain above an 11% level. Medicare medical cost trend is now expected below the initial estimate of around 10%, with full-year Medicare Advantage enrollment expected to decline by approximately 1.1 million and Medicare margins above 3%. Optum Health is re-centering on integrated value-based care, and Optum Rx and Optum Insight are described as on plan. Commercial margin recovery is now expected to extend beyond 2027 due to persistent elevated trend, which management attributes partly to the No Surprises Act independent dispute resolution process and provider billing intensity.
Key takeaways
- Adjusted EPS of $6.38 in Q2 2026 compared to $4.08 in the prior year, with operating earnings of $8 billion up 55% year-over-year.
- Medicare medical cost trend is tracking below the initial 2026 estimate of around 10%, helped by benefit design, care management, network curation, prior year development, a more favorable respiratory season and weather.
- Commercial medical cost trends are modestly above the previously cited 11% level, driven by the No Surprises Act IDR process and more aggressive provider billing and coding intensity, extending commercial margin recovery past 2027.
- Optum Health improved care management and operating discipline, with initiatives cited including roughly 10% fewer hospitalizations in Western and Southern regions and a 5% year-over-year gain in patient experience.
- UnitedHealthcare committed to eliminating 30% of prior authorization volume and nearly two-thirds of prior authorization requirements for pediatric care by the end of 2026.
Financial highlights
- Q2 2026 adjusted EPS was $6.38 versus $4.08 in the prior year; total revenues were $112 billion, largely consistent with the prior year.
- Q2 2026 operating earnings were $8 billion, up 55% year-over-year; the medical care ratio was 86.7% versus 89.4% in Q2 2025, including $860 million of net favorable prior period medical development.
- Operating cash flows in the quarter were approximately $11 billion, or 1.9 times net income; days claims payable was 47 days, up about 2.5 days from a year ago.
- The operating cost ratio was 12.7% versus 12.3% a year ago, and the debt to capital ratio was 41.2% versus 44.1% one year ago.
Guidance
- Full-year 2026 adjusted EPS guidance is $19.50 to $20, with slightly more earnings in Q3 relative to Q4.
- Full-year 2026 guidance includes UnitedHealthcare operating earnings of at least $12 billion and Optum Health operating earnings of at least $2.2 billion.
- Full-year 2026 medical care ratio is expected at 88.1% plus or minus 25 basis points, with the operating cost ratio at the higher end of the previously discussed range.
- Total share repurchases in 2026 are now expected to be at least $5 billion versus initial guidance of $2.5 billion, and the debt to capital ratio is targeted at approximately 40% by the end of 2026.
Q&A themes
- Commercial cost trend pressure from the No Surprises Act IDR process, provider coding intensity, specialty pharmacy and GLP-1 costs, with margin recovery pushed past 2027.
- Medicare Advantage trend tracking below 2026 planning assumptions, though management said this is not an inflection point and declined to give a new point estimate until the next call.
- Medicaid 2026 margins expected within the previously communicated range of -1% to -1.7%, with annualized 2026 rate impacts around 6%-7% still lagging elevated medical trend.
- Optum Health value-based care margins performing slightly better than expected, with 2027 payer contracting largely complete and second-half investments continuing.
Risks
- Commercial medical cost trends remain stubbornly high and modestly above the previously cited 11% level, extending the timeline for commercial margin recovery beyond 2027.
- Medicare medical cost trends remain well above historical levels even though below planning assumptions, and management said this does not represent an inflection point.
- Medicaid margins are expected to remain pressured for 2026 as reimbursement rates lag underlying medical cost trends.
FY2026 Q12026-04-21
Earnings calls
AI summary
positiveUnitedHealth reported Q1 2026 adjusted earnings per share of $7.23, well ahead of expectations, with all major business segments exceeding plan. UnitedHealthcare achieved modest favorability in government programs with pricing improving relative to elevated healthcare cost trends, while Optum Health delivered $1.3 billion in adjusted earnings reflecting pricing and operational improvements. The company raised full-year guidance to greater than $18.25 per share and expects approximately 2/3 of earnings in the first half.
Key takeaways
- Q1 adjusted EPS of $7.23 exceeded expectations; all operating segments exceeded internal plan
- Medical care ratio improved to 83.9% from 84.8% YoY driven by pricing discipline and strong cost management
- Optum Health adjusted earnings of $1.3 billion reflect disciplined value-based care model and operational improvements; West region saw 35% reduction in SNF admissions
- Medicare Advantage pricing assumptions of ~10% are tracking appropriately with elevated utilization trends consistent with 2025 levels
- Company investing $1.5 billion in AI-related initiatives in 2026 with AI-first products like Optum Real seeing early traction
Financial highlights
- Total revenues $111.7 billion, up 2% YoY; domestic members 49.1 million vs 49.8 million at end of 2025
- Operating cash flows $8.9 billion (1.4x net income); debt-to-capital ratio 42.9%, on track to 40% year-end goal
- Medical care ratio 83.9% vs 84.8% prior year; operating cost ratio 13.8%
- Prior period development (PYD) contribution approximately $500 million net for the quarter
Guidance
- Full year 2026 adjusted EPS guidance raised to greater than $18.25 per share
- Approximately 2/3 of earnings expected in first half of year; UnitedHealthcare earnings over 75% weighted to first half
- Medicare Advantage member attrition expected to center around 1.3 million decline in 2026
- Expect Medicaid negative margins in 2026 with modest improvements beginning in 2027; ACA membership expected to decline by approximately 1/3 in 2026
Q&A themes
- Medicare Advantage trend running at elevated levels consistent with 7-10% expectations; modest favorability in government programs with no inflection point expected
- Optum Health outperformance driven by clinical management, medical restating favorably, and operating improvements including 12% YoY increase in patient-facing hours
- PBM legislation accounted for in guidance; company leading on transparency and practice standards; 100% of independent pharmacies reimbursed at cost-based mechanism
- AI investment returning 2:1 conservative ROI expectation with payback for many programs within 12-18 months; Optum Real processing 0.5 billion transactions YoY with 2.5 billion expected year-end
Risks
- Medicaid continues to face high trend and insufficient funding; community and state results reflect ongoing pressures in state-based rate environments
- Potential future Medicare Advantage risk adjustment model changes scheduled for 2028 could impact complex chronic condition reimbursement
- Tennessee legislation concerning for specialty and behavioral health pharmacy access affecting approximately 150,000 state residents with complex conditions
FY2025 Q42026-01-27
Earnings calls
AI summary
mixedUnitedHealth completed 2025 with solid execution despite a $1.6 billion non-cash charge primarily related to Optum restructuring and contract reserves. The company is pursuing strategic refocus across UnitedHealthcare and Optum segments, with plans for margin recovery through repricing, network optimization, and AI-driven productivity improvements. 2026 guidance reflects modest growth across all business segments while addressing structural headwinds from Medicare funding reductions and elevated medical cost trends.
Key takeaways
- UnitedHealthcare expects approximately 50 basis points of Medicare margin improvement in 2026 despite 1.3-1.4 million member contraction from intentional repricing and margin recovery strategy
- Optum segments expect low to high single-digit earnings growth with 20-90 basis points of margin expansion; OptumHealth margins to improve approximately 30 basis points with 9% earnings growth
- Company expects approximately $1 billion in operating cost reductions in 2026, with over 80% of member calls leveraging AI tools, and plans $1.5 billion in AI investments
- 2026 revenues expected near $440 billion with operating cash flow of at least $18 billion; medical care ratio expected at 88.8% plus or minus 50 basis points
Financial highlights
- FY2025 adjusted EPS of $16.35 slightly ahead of expectations; full year revenues of approximately $448 billion, reflecting 12% growth
- Medical care ratio of 89.1% in 2025, with operating cost ratio of 13.3% demonstrating disciplined management
- Operating cash flows of $19.7 billion in 2025, approximately 1.5 times net income; 2026 expected cash flow of at least $18 billion or about 1.1 times net income
- 2025 results included $1.6 billion net of tax non-cash charge with three components: $800 million cyber-related true-up, $440 million net gain on portfolio optimization, and $2.5 billion restructuring charge
Guidance
- 2026 adjusted EPS guidance of greater than $17.75, representing at least 8.6% growth; net earnings of at least $17.10 per share
- UnitedHealthcare expects approximately 13% adjusted operating earnings growth from margin recovery efforts and repricing; membership contraction of 2.3-2.8 million expected
- Medicare Advantage medical cost trend of 10% expected for 2026, with 1.3-1.4 million member contraction including group, individual, and dual plans
- Medicaid membership contraction of 565,000-715,000 people expected due to reduced eligibility and state funding shortfalls; rate increases anticipated in 6-7% range but below medical trend
Q&A themes
- 2027 Medicare Advantage outlook uncertain pending CMS rate finalization; advance notice published suggests potential benefit reductions and need to reassess geographic and product footprint
- OptumHealth fourth quarter underperformance relative to guidance largely reflected restructuring actions and one-time items now resolved; baseline adjusted earnings approximately $1.5 billion moving forward
- OptumRx winning 800 new customers in 2026 driven by affordability, transparency, and execution; customers save over $2,200 annually per member; 95% of customers elected full rebate pass-through
- Commercial group business January performance strong and competitive; company expects to close more than half the gap between 2025 and historical margin range in 2026
Risks
- 2027 Medicare Advantage rates from CMS advance notice may require significant benefit reductions and membership adjustments; seniors expected to face reduced choice and affordability challenges across the sector
- Medicaid business continues experiencing rate and acuity mismatch with 6-7% rate increases projected below elevated medical trends, creating ongoing margin pressure
- OptumHealth turnaround execution risk remains with margin expansion dependent on achieving consistency across markets and successful network optimization; long-term 6-8% margin target requires continued operational improvement
FY2025 Q32025-10-28
Earnings calls
AI summary
mixedUnitedHealth Group is executing a multi-year recovery plan addressing underperformance through repricing actions, operational discipline, and strategic portfolio rationalization. The company expects solid earnings growth in 2026 driven by UnitedHealthcare margin expansion and measured progress in Optum businesses, while managing significant Medicare funding headwinds from V28 cuts. Management emphasizes returning to mission-driven culture while balancing near-term recovery with investments for sustainable double-digit growth from 2027 forward.
Key takeaways
- UnitedHealthcare repricing positioned for 2026 margin growth; Medicare Advantage membership expected to decline ~1 million in 2026 as company takes disciplined approach to benefit design and network management
- Optum Health refocusing on value-based care model with narrower, more integrated provider networks; 10% membership decline expected in 2026 before return to growth in 2027; targeting 6%-8% long-term margins
- V28 Medicare funding cuts represent $6+ billion enterprise headwind in 2026; company expects to offset approximately half through payer contracting and has completed 90% of value-based care payer contracts for 2026
- Q3 operating cash flow of $5.9 billion; company expects $16 billion full-year 2026 operating cash flow and anticipates reinstituting share buybacks and strategic acquisitions in second half of 2026 as debt-to-capital ratio approaches 40%
- Non-GAAP charge of low single-digit billion dollars expected (substantially noncash) for planned restructuring including international footprint reduction, Optum Health geographic consolidation, and Optum Financial realignment
Financial highlights
- Q3 2025 adjusted earnings per share: $2.92, slightly ahead of expectations
- Q3 2025 revenues: $113+ billion, reflecting 12% year-over-year growth and domestic membership expansion of 780,000+ lives year-to-date
- Q3 medical care ratio: 89.9% versus 85.2% prior year; full year trending toward lower end of prior guidance
- Q3 operating cost ratio: 13.5%, reflecting investments of $450+ million in employee incentives and UnitedHealth Foundation contributions
Guidance
- 2025 full year: Medical cost trends expected to remain historically high but consistent with prior guidance; Medicare Advantage trend forecast ~7.5%; Optum Health margins expected to end just under 3% with value-based care margins under 1%
- 2026 outlook: Repricing actions expected to drive margin improvement across UnitedHealthcare businesses; Commercial segment expected to be ~150 basis points below 7%-9% long-term target; Medicaid margins expected to decline further but viewed as trough year for Medicaid performance
- 2026 and beyond: Full guidance to be provided in January; company positioned to return to solid earnings growth in 2026 with acceleration toward higher and sustainable double-digit growth beginning 2027; expects to reach upper half of 2%-4% Medicare margin target range by 2027
- Debt reduction plan: Debt-to-capital ratio expected to trend toward 40% by second half of 2026; capital deployment priorities are debt reduction, followed by share buybacks and strategic acquisitions
Q&A themes
- Optum Health value-based care TAM and competitive positioning: Management confirmed strong competitive position with significant growth potential; emphasized commitment to expanding VBC across Medicare Advantage while maintaining operating discipline around appropriate network, providers, and risk profile
- Optum Insight investment and AI acceleration: New leadership announced focus on AI-first transformation across products and platforms; highlighted recent product launches (Optum Real, Optum Integrity One, Crimson AI) showing strong early adoption and ROI metrics
- Medicare Advantage industry dynamics: Management expressed optimism about new administration's receptivity to constructive conversations on MA modernization versus prior administration; emphasized importance of program stability for continued growth
- Provider coding and trend management: Acknowledged aggressive provider coding practices as meaningful trend driver; outlined multi-pronged approach including network actions, AI-enhanced payment integrity programs, and clinical affordability initiatives to address outlier situations
Risks
- External headwinds persist: Third year of approximately $50 billion in industry-wide Medicare funding cuts from prior administration combined with Medicaid funding and program pressures continue to constrain earnings growth in 2026
- Optum Health execution risk: Success of value-based care refocus depends on effective integration and network restructuring; 10% membership decline in 2026 represents execution and retention risk before expected return to growth in 2027
- Regulatory and program uncertainty: IDR (Independent Dispute Resolution) process impact on trends remains uncertain; CMS policy changes under new administration, while encouraging, represent ongoing policy uncertainty affecting forward guidance
FY2025 Q22025-07-29
Earnings calls
AI summary
negativeUnitedHealth Group significantly revised its 2025 financial outlook downward, citing $6.5 billion in additional medical costs driven primarily by underestimated pricing assumptions and elevated care utilization trends. The company expects full-year adjusted EPS of at least $16, down from prior expectations, with margin recovery efforts focused on 2026 repricing and operational improvements across UnitedHealthcare and Optum Health.
Key takeaways
- 2025 earnings shortfall of $6.5 billion: $3.6 billion in Medicare Advantage, $2.3 billion in commercial (split between ACA and employer), with remainder in Medicaid and behavioral health at 20% trend
- Medicare Advantage medical cost trend now estimated at 7.5% versus initial 5%+ assumption; broad-based pressure from physician/outpatient care intensity and increased ER utilization
- Optum Health value-based care business down $3.6 billion, driven by V28 funding cuts ($11 billion three-year headwind), unfavorable enrollment mix of new/complex patients, and medical trend acceleration
- 2026 pricing strategy includes significant Medicare Advantage benefit cuts, plan exits of 600,000+ members, double-digit commercial rate increases, and Medicaid margin compression with expected losses in non-dual segment
- Leadership changes across enterprise including new CFO, COO, and CEO roles at Optum Health and Insight; independent expert reviews underway for critical processes including risk assessment and care management
Financial highlights
- Q2 2025 adjusted EPS of $4.08 below prior year; full-year adjusted EPS guidance at least $16 per share
- Q2 revenues of $112 billion, up 13% year-over-year; UnitedHealthcare revenues $86.1 billion with operating earnings down $1.9 billion to $2.1 billion
- Full-year 2025 medical care ratio revised to 89.25% ± 25 bps (previously 86.5%); second half expected at just under 91.5% with Q4 highest
- Optum Health earnings down $6.6 billion from expectations; OptumRx revenue growth of $18 billion (13%) with earnings growth of ~$200 million (4%)
Guidance
- 2026 Medicare Advantage target margin range of 2% to 4% (adjusted for IRA Part D revenue impact); expect 2.5-3% range achievable through benefit reductions and pricing for ~10% trend
- 2026 commercial margins expected to approach but fall slightly short of 7-9% target range, with recovery expected in 2027
- 2026 Medicaid margins expected at negative 1% to negative 1.7% for non-dual segment due to continued rate/acuity lag
- Optum Health long-term margin target of 6-8% (value-based care at 5%); 2026 value-based care margins expected to remain at ~1% before advancing in 2027 and beyond
Q&A themes
- Medicare Advantage margin path: 2-2.5% for balance of 2025, expanding to 2.5-3% in 2026, reaching midpoint by 2027 through benefit cuts, trend pricing, and plan exits
- Optum Health cohort analysis: 2024-2025 new patients at negative margins, 2022-2023 cohorts at 2% margins, 2021 and prior at 8%+ margins; improvement expected as new cohorts mature
- V28 headwinds: $11 billion three-year impact with $7 billion through 2025; 2026 represents final year of V28 phase-in with mitigation efforts addressing ~50% of remaining $4 billion headwind
- Portfolio actions: Company paused previously planned divestitures and business optimization actions (~$1 billion impact), choosing instead to focus on performance improvement of existing portfolio
Risks
- Generational pullback in Medicare funding through 2026, unprecedented medical cost trends in service intensity and unit prices, and aggressive provider coding/billing practices creating sustained headwinds
- Medicaid and ACA exchange market contraction risk; projected expiration of ACA premium subsidies expected to drive significant membership decline and adverse selection dynamics
- Optum Health execution risk in value-based care transition with 40% of patients new since early 2024 at negative margins; long timeline to margin recovery and uncertain path to 6-8% target
Company news
Reuters, WSJ, Bloomberg and FT first, as far as our news provider delivers them; other publishers behind the second filter. Headlines link to the publisher.- From Verizon to UnitedHealth, Corporate America Is Balking at ‘Tokenized' Stocks
- UnitedHealth Charts Continued Turnaround
- Texas AG Paxton Launches Investigation Into UnitedHealth Group
- Robert Hunter to be new UnitedHealthcare president
- UnitedHealthcare to drop prior authorization requirements for range of conditions from Oct. 1
Company data
Company intelligence
Updated: Nov 22, 2026, 12:27 PM UTC
Company data
Company intelligence
Company profile
- Sector
- Healthcare
- Industry
- Medical - Healthcare Plans
- Chief executive
- Stephen J. Hemsley
- Employees
- 390,000
- IPO date
- Oct 17, 1984
- Country
- US
- Exchange
- New York Stock Exchange
Rating factors
- Return on equityi
- 4/5
- Return on assetsi
- 4/5
- Debt to equityi
- 1/5
- Price to earningsi
- 2/5
- Price to booki
- 2/5
Company press releases
Congressional disclosures
Senate
House
Market cap history
Largest fund holders
| Fund | Weight | Shares held |
|---|---|---|
| VCPA.S | 0.73% | 34.9M |
| VOO | 0.56% | 23.9M |
| VTI | 0.5% | 22.5M |
| IVV | 0.58% | 12.1M |
| 1657.T | 0.44% | 12.1M |
| XAW.TO | 0.34% | 12.1M |
| XUU.TO | 0.51% | 12.1M |
| SCHD | 4.01% | 12M |
| SPY | 0.58% | 11.1M |
| FXAIX | 0.5% | 10.8M |
| VSCA.S | 0.3% | 9.1M |
| VTV | 1.31% | 8.6M |
Analyst track record
How the analysts covering UNH have done: ratings, price-target accuracy and the measured reaction after their calls.
| 12 months | 3 years | |
|---|---|---|
| Ratings | 147 | 534 |
| Analysts | 27 | 32 |
| Buy / hold / sell | 124 / 22 / 1 | 473 / 55 / 6 |
| Upgrades / downgrades / initiations | 6 / 1 / 1 | 11 / 17 / 6 |
| Price targets hit / missed | 7 / 129 (5%) | 43 / 446 (9%) |
| Avg. return after a rating (TipRanks) | -22.1% | -28.5% |
| Best / worst call | +15.2% / -37.8% | +66.9% / -53.8% |
After buy calls on this stock: median 21-day move +1.1% vs S&P 500 -0.6% (n = 477)
Most accurate on this stock
Share of an analyst's price targets on this stock that the price reached within 12 months (our measurement over the last 3 years, at least 8 targets). It describes past calls, not the odds of the current one.
- Scott FidelGoldman Sachs91% hit rate on this stock · 11 targets measuredBuyno targetNov 19, 2026
- Michael WiederhornOppenheimer73% hit rate on this stock · 11 targets measuredBuytarget $500Jul 17, 2026
- Ann HynesMizuho Securities71% hit rate on this stock · 17 targets measuredBuytarget $500Nov 15, 2026
Latest ratings
| Date | Analyst | Call | Target | |
|---|---|---|---|---|
| Nov 20, 2026 | Ryan LangstonTD CowenNov 20, 2026 | BuyUpgraded | $455↗ | article ↗ |
| Nov 19, 2026 | Scott FidelGoldman SachsNov 19, 2026 | BuyMaintained | –↗ | article ↗ |
| Nov 18, 2026 | Lance WilkesBernsteinNov 18, 2026 | BuyReiterated | $500↗ | article ↗ |
| Nov 15, 2026 | Ann HynesMizuho SecuritiesNov 15, 2026 | BuyMaintained | $500↗ | article ↗ |
| Nov 10, 2026 | Elizabeth Anderson CFAEvercore ISINov 10, 2026 | BuyMaintained | $480↗ | article ↗ |
Share of analysts per call each month (latest call per analyst within 180 days). Targets and closes in USD.
TipRanks data · computed Nov 20, 2026 · 147 ratings
Frequently asked questions
Where can I trade UNH perpetual futures?
UnitedHealth Group Incorporated (UNH) perpetual futures trade on 14 crypto venues, including Deepcoin, BingX, XT.com. PerpEquities compares them by live price, funding rate, open interest and liquidity.
Can I trade UNH around the clock?
Yes. Unlike the underlying stock, UNH perpetuals trade 24/7 — including weekends and outside regular market hours.
What is the funding rate on UNH perpetuals?
Right now the UNH perp funding rate is 0.0% annualized (venue median), ranging from -4.0% to +5.5% across 14 venues. A positive rate means longs pay shorts. PerpEquities shows the live rate and its history for every venue.
How does the UNH perp price compare to the UnitedHealth Group Incorporated stock?
The venue-median UNH perp mark is $335.9 versus a reference stock price of $334.8, a basis of +0.3%. Perps follow the stock through an index price; the gap widens when funding or liquidity diverge between venues.
What is a UNH perpetual future?
A UNH perpetual is a derivative that tracks the price of UnitedHealth Group Incorporated with no expiry date. It lets you take long or short exposure to UnitedHealth Group Incorporated on crypto venues, around the clock.
What is UNHUSDT perpetual?
UNHUSDT is the symbol most crypto exchanges use for the UnitedHealth Group Incorporated perpetual settled in USDT (Tether). It tracks the UNH share price through an index, trades 24/7 with leverage and never expires.
XT.com
HTX
MEXC
Bitunix
Binance
BloFin
LBank
Bitget
OKX
Gate.io
Bybit
Crypto.com Exchange
Deepcoin
BingX